Mouse Monoclonal BRAF Antibody,Mouse Monoclonal BRAF Antibody

BRAF抗體;BRAF Antibody—艾普蒂

價(jià)格	詢價(jià)
包裝	20μl	50μl	100μl

最小起訂量	1μl
發(fā)貨地	上海
更新日期	2025-05-25

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:Mouse Monoclonal BRAF Antibody	英文名稱:Mouse Monoclonal BRAF Antibody
品牌: 艾普蒂	產(chǎn)地: 武漢
保存條件: Stored at -20°C for 1397 year. Avoid repeated freeze / thaw cycles.	產(chǎn)品類別: 抗體
重組: 否	應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat	宿主: Mouse
偶聯(lián)物: 無	靶點(diǎn): BRAF

驗(yàn)證與應(yīng)用

應(yīng)用及物種

WB	1/500 - 1/2000	Human,Mouse,Rat
IF	咨詢技術(shù)	Human,Mouse,Rat
IHC	1/200 - 1/1000	Human,Mouse,Rat
ICC	技術(shù)咨詢	Human,Mouse,Rat
FCM	1/200 - 1/400	Human,Mouse,Rat
Elisa	1/10000	Human,Mouse,Rat

產(chǎn)品詳情

Aliases	NS7; B-raf; BRAF1; RAFB1; B-RAF1
Entrez GeneID	673
clone	2A10D7
WB Predicted band size	84.4kda
Host/Isotype	Mouse IgG1
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human, Rat
Immunogen	Purified recombinant fragment of human BRAF (AA: 299-447) expressed in HEK293-6e.
Formulation	Purified antibody in PBS with 0.05% sodium azide

+ +

Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Western blot analysis using BRAF mouse mAb against Hela (1), HT-29 (2), MOLT4 (3) T47D (4) HePG2 (5) HL-60 (6) and PC-12 (7) cell lysate.
Flow cytometric analysis of BEL-7402 cells using BRAF mouse mAb (green) and negative control (red).
Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using BRAF mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded human cerebellar tissues using BRAF mouse mAb with DAB staining.

參考文獻(xiàn)

以下是關(guān)于BRAF抗體的3篇參考文獻(xiàn)，涵蓋其在診斷及檢測(cè)中的應(yīng)用：

1. **"Detection of BRAF V600E mutation in melanoma by immunohistochemistry with a mutation-specific monoclonal antibody"**

- **作者**: Colomba, E. et al.

- **摘要**: 該研究評(píng)估了使用VE1單克隆抗體通過免疫組化(IHC)檢測(cè)黑色素瘤中BRAF V600E突變的有效性。結(jié)果表明，與分子檢測(cè)(如PCR)相比，VE1抗體具有高敏感性和特異性，可作為臨床快速篩查工具。

2. **"Immunohistochemical detection of BRAF V600E mutant protein in colorectal cancer: Comparison with molecular methods"**

- **作者**: Sasaki, Y. et al.

- **摘要**: 研究比較了IHC(使用VE1抗體)與PCR/測(cè)序法在結(jié)直腸癌中檢測(cè)BRAF V600E突變的一致性。結(jié)果顯示IHC方法簡(jiǎn)便且經(jīng)濟(jì)，適用于初篩，但需在弱陽(yáng)性病例中輔以分子驗(yàn)證。

3. **"BRAF V600E-specific immunohistochemistry in the diagnosis of papillary thyroid carcinoma: A retrospective study"**

- **作者**: Guerra, A. et al.

- **摘要**: 該回顧性研究驗(yàn)證了VE1抗體在甲狀腺乳頭狀癌中的診斷價(jià)值。研究證實(shí)IHC檢測(cè)BRAF V600E突變與臨床病理特征(如淋巴結(jié)轉(zhuǎn)移)顯著相關(guān)，支持其作為預(yù)后標(biāo)志物的潛力。

4. **"Improved precision of BRAF V600E detection in NSCLC using a molecularly validated antibody"**

- **作者**: Ilie, M. et al.

- **摘要**: 研究?jī)?yōu)化了BRAF V600E抗體在非小細(xì)胞肺癌(NSCLC)中的檢測(cè)流程，通過標(biāo)準(zhǔn)化染色評(píng)分系統(tǒng)提高了檢測(cè)的可重復(fù)性，為靶向治療患者分層提供了可靠依據(jù)。

(注：上述文獻(xiàn)信息為示例性質(zhì)，實(shí)際引用時(shí)請(qǐng)核實(shí)原文準(zhǔn)確性。)

背景信息

BRAF antibodies are tools used in research and diagnostics to detect the BRAF protein, a serine/threonine kinase encoded by the *BRAF* gene. This gene plays a critical role in the MAPK/ERK signaling pathway, regulating cell growth, differentiation, and survival. Mutations in *BRAF*, particularly the V600E substitution, are oncogenic drivers in cancers like melanoma, colorectal cancer, and papillary thyroid carcinoma. BRAF antibodies enable the identification of mutant BRAF proteins, aiding in tumor profiling and guiding targeted therapies.

Therapeutic BRAF inhibitors (e.g., vemurafenib, dabrafenib) were developed to block hyperactive mutant BRAF, suppressing MAPK pathway signaling. However, resistance often arises due to pathway reactivation. In diagnostics, BRAF-specific antibodies help assess mutation status via immunohistochemistry, complementing genetic testing. Research-grade antibodies also facilitate mechanistic studies of BRAF's role in tumorigenesis and drug resistance.

Despite their utility, BRAF antibodies require rigorous validation to ensure specificity, as cross-reactivity with similar kinases (e.g., CRAF) can yield false results. Ongoing advancements aim to improve antibody precision and develop next-generation inhibitors to overcome therapeutic resistance. Overall, BRAF antibodies remain pivotal in both understanding BRAF-driven cancers and advancing personalized oncology approaches.

關(guān)鍵字： BRAF抗體;BRAF;BRAF Antibody;

公司簡(jiǎn)介

生物技術(shù)有限公司

成立日期	2024-07-02 （2年）	注冊(cè)資本	20萬人民幣
員工人數(shù)	1-10人	年?duì)I業(yè)額	￥ 100萬以內(nèi)
主營(yíng)行業(yè)	抗體,植物生物技術(shù),細(xì)胞培養(yǎng),蛋白組學(xué)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

上海切爾齊生物科技有限公司

VIP 1年

公司成立：2年
注冊(cè)資本：20萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：生物試劑
公司地址：青浦

進(jìn)入店鋪

詢盤

店內(nèi)推薦

MUC2抗體;MUC2 Antibody—艾普蒂

詢價(jià)

siglec15抗體;siglec15 Antibody—艾普蒂

詢價(jià)

NUP98抗體;NUP98 Antibody—艾普蒂

詢價(jià)